Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetyltransferase 14 (NAT14) is a putative member of the acetyltransferase enzyme family that in humans is encoded by the NAT14 gene. It is predicted to possess N-acetyltransferase and acyltransferase activity, but experimental evidence for such enzymatic function remains lacking, and its canonical substrates have not been established[1][2][3][7][9]. NAT14 has also been suggested to function as a transcription factor, possibly regulating the expression of coproporphyrinogen oxidase by binding to promoter elements[1][5][6]. The protein is reportedly localized to the nucleus and may be involved in the regulation of DNA-templated transcription and cell cycle processes[1][5][6]. There is no established therapeutic relevance or known drugs targeting NAT14, nor clear roles as a clinical biomarker or disease gene[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetyltransferase 14 (NAT14).